Safety of first-line triple therapy with a potassium-competitive acid blocker for Helicobacter pylori eradication in children
Journal of Gastroenterology Nov 10, 2017
Kusano C, et al. - The researchers investigated the safety of first-line triple therapy with a potassium-competitive acid blocker (P-CAB) for Helicobacter pylori (H. pylori) eradication in children. For H. pylori eradication in children, first-line triple therapy with a P-CAB was safe.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
